Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics.

The ADHD Drugs in Development market research report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for ADHD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for ADHD and features dormant and discontinued projects.

ADHD Pipeline Drugs Market Targets

Some of the targets of the ADHD pipeline drugs market are Sodium Dependent Noradrenaline Transporter, Sodium Dependent Dopamine Transporter, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 1A, D2 Dopamine Receptor, D4 Dopamine Receptor, 5-Hydroxytryptamine Receptor, 5-Hydroxytryptamine Receptor 1B.

ADHD pipeline drugs market, by targets

ADHD pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of ADHD Pipeline Drugs Market

Some of the mechanisms of action of the ADHD pipeline drugs market are Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D3 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Agonist, D4 Dopamine Receptor Agonist, and 5-Hydroxytryptamine Receptor 1B Agonist.

ADHD pipeline drugs market, by mechanisms of action

ADHD pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in ADHD Pipeline Drugs Market

The routes of administration in the ADHD pipeline drugs market are oral, transdermal, nasal, and subcutaneous.

ADHD pipeline drugs market, by routes of administration

ADHD pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in ADHD Pipeline Drugs Market

The molecule types in the ADHD pipeline drugs market are small molecule, biologic, and enzyme.

ADHD pipeline drugs market, by molecule types

ADHD pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key ADHD Pipeline Drugs Market Companies

Some of the key companies in the ADHD pipeline drugs market are 3Z ehf, NLS Pharmaceutics AG, Tris Pharma Inc, Supernus Pharmaceuticals Inc, Cingulate Therapeutics LLC, Ensysce Biosciences Inc, MD Healthcare Inc, 4P-Pharma SAS, ABVC BioPharma Inc, and AgoneX Biopharmaceuticals Inc.

ADHD pipeline drugs market, by key companies

ADHD pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Sodium Dependent Noradrenaline Transporter, Sodium Dependent Dopamine Transporter, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 1A, D2 Dopamine Receptor, D4 Dopamine Receptor, 5-Hydroxytryptamine Receptor, 5-Hydroxytryptamine Receptor 1B
Mechanisms of Action Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D3 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Agonist, D4 Dopamine Receptor Agonist, and 5-Hydroxytryptamine Receptor 1B Agonist
Routes of Administration Oral, Transdermal, Nasal, and Subcutaneous
Molecule Types Small Molecule, Biologic, and Enzyme
Key Companies 3Z ehf, NLS Pharmaceutics AG, Tris Pharma Inc, Supernus Pharmaceuticals Inc, Cingulate Therapeutics LLC, Ensysce Biosciences Inc, MD Healthcare Inc, 4P-Pharma SAS, ABVC BioPharma Inc, and AgoneX Biopharmaceuticals Inc

Scope 

This report provides:

  • A snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Reviews of pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3Z ehf
4P-Pharma SAS
ABVC BioPharma Inc
AgoneX Biopharmaceuticals Inc
Altus Formulation Inc
Amarantus Bioscience Holdings Inc
Arbor Pharmaceuticals LLC
Attentive Therapeutics Inc
Avekshan LLC
BCWorld Pharm Co Ltd
Cennerv Pharma (S) Pte Ltd
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Commave Therapeutics SA
Curemark LLC
DD Therapeutics LLC
DURECT Corp
Eli Lilly and Co
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Highland Therapeutics Inc
Hyloris Pharmaceuticals SA
INVENT Pharmaceuticals Inc
Kashiv BioSciences LLC
KemPharm Inc
Lennham Pharmaceuticals Inc
M et P Pharma AG
Marvel Biotechnology Inc
MD Healthcare Inc
Mind Medicine MindMed Inc
Mindset Pharma Inc
NeuroNascent Inc
NLS Pharmaceutics AG
Nobias Therapeutics Inc
NutriBand Inc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
P2D Inc
PolyCore Therapeutics LLC
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shenox Pharmaceuticals LLC
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taho Pharmaceuticals Ltd
Tonix Pharmaceuticals Holding Corp
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Yichang Renfu Pharmaceutical Co Ltd
Yuyu Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) – Overview

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development

3Z ehf

4P-Pharma SAS

ABVC BioPharma Inc

AgoneX Biopharmaceuticals Inc

Altus Formulation Inc

Amarantus Bioscience Holdings Inc

Arbor Pharmaceuticals LLC

Attentive Therapeutics Inc

Avekshan LLC

BCWorld Pharm Co Ltd

Cennerv Pharma (S) Pte Ltd

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Commave Therapeutics SA

Curemark LLC

DD Therapeutics LLC

DURECT Corp

Eli Lilly and Co

EncepHeal Therapeutics Inc

Ensysce Biosciences Inc

Highland Therapeutics Inc

Hyloris Pharmaceuticals SA

INVENT Pharmaceuticals Inc

Kashiv BioSciences LLC

KemPharm Inc

Lennham Pharmaceuticals Inc

M et P Pharma AG

Marvel Biotechnology Inc

MD Healthcare Inc

Mind Medicine MindMed Inc

Mindset Pharma Inc

NeuroNascent Inc

NLS Pharmaceutics AG

Nobias Therapeutics Inc

NutriBand Inc

Oryzon Genomics SA

Otsuka Pharmaceutical Co Ltd

OWP Pharmaceuticals Inc

P2D Inc

PolyCore Therapeutics LLC

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Shenox Pharmaceuticals LLC

Shionogi & Co Ltd

SK Biopharmaceuticals Co Ltd

Supernus Pharmaceuticals Inc

Suven Life Sciences Ltd

Taho Pharmaceuticals Ltd

Tonix Pharmaceuticals Holding Corp

Tris Pharma Inc

Vallon Pharmaceuticals Inc

Yichang Renfu Pharmaceutical Co Ltd

Yuyu Pharma Inc

Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profiles

(methylphenidate hydrochloride + cyproheptadine) ER – Drug Profile

Product Description

Mechanism Of Action

(methylphenidate hydrochloride + naltrexone hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

3Z-20001 – Drug Profile

Product Description

Mechanism Of Action

3Z-20002 – Drug Profile

Product Description

Mechanism Of Action

3Z-20003 – Drug Profile

Product Description

Mechanism Of Action

3Z-20004 – Drug Profile

Product Description

Mechanism Of Action

4P-003 – Drug Profile

Product Description

Mechanism Of Action

ABV-1505 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AFI-002 – Drug Profile

Product Description

Mechanism Of Action

amfetamine ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

AR-19 – Drug Profile

Product Description

Mechanism Of Action

History of Events

atomoxetine – Drug Profile

Product Description

Mechanism Of Action

atomoxetine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

BCWPE-003 – Drug Profile

Product Description

Mechanism Of Action

brilaroxazine – Drug Profile

Product Description

Mechanism Of Action

History of Events

CB-8411 – Drug Profile

Product Description

Mechanism Of Action

centanafadine SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-4612 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CX-717 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dexmethylphenidate hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

dextroamphetamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

dextroamphetamine MR – Drug Profile

Product Description

Mechanism Of Action

History of Events

dopamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug for Attention Deficit Hyperactivity Disorder and Obesity – Drug Profile

Product Description

Mechanism Of Action

Drugs for Attention Deficit Hyperactivity Disorder and Lymphatic Anomalies – Drug Profile

Product Description

Mechanism Of Action

Drugs for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

edivoxetine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

eltoprazine – Drug Profile

Product Description

Mechanism Of Action

History of Events

histamine dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

INV-400 – Drug Profile

Product Description

Mechanism Of Action

JJC-8091 – Drug Profile

Product Description

Mechanism Of Action

History of Events

K-129 – Drug Profile

Product Description

Mechanism Of Action

KP-484 – Drug Profile

Product Description

Mechanism Of Action

History of Events

KP-922 – Drug Profile

Product Description

Mechanism Of Action

KR-33028 – Drug Profile

Product Description

Mechanism Of Action

levofacetoperane – Drug Profile

Product Description

Mechanism Of Action

History of Events

lisdexamphetamine dimesylate – Drug Profile

Product Description

Mechanism Of Action

lysergic acid diethylamide – Drug Profile

Product Description

Mechanism Of Action

History of Events

mazindol CR – Drug Profile

Product Description

Mechanism Of Action

History of Events

MB-204 – Drug Profile

Product Description

Mechanism Of Action

MDH-001 – Drug Profile

Product Description

Mechanism Of Action

MDH-204 – Drug Profile

Product Description

Mechanism Of Action

methylphenidate – Drug Profile

Product Description

Mechanism Of Action

methylphenidate ER – Drug Profile

Product Description

Mechanism Of Action

methylphenidate hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

methylphenidate hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

methylphenidate IR – Drug Profile

Product Description

Mechanism Of Action

NLS-4 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NLS-8 – Drug Profile

Product Description

Mechanism Of Action

NNI-351 – Drug Profile

Product Description

Mechanism Of Action

PCT-3012 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PD-3044 – Drug Profile

Product Description

Mechanism Of Action

PF-8001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-8026 – Drug Profile

Product Description

Mechanism Of Action

History of Events

S-874713 – Drug Profile

Product Description

Mechanism Of Action

SHX-009 – Drug Profile

Product Description

Mechanism Of Action

SKL-13865 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize ADORA for Central Nervous System – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize 5-HT2A for Alzheimer’s Disease and Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit SLC9A9 for ADHD – Drug Profile

Product Description

Mechanism Of Action

SPN-443 – Drug Profile

Product Description

Mechanism Of Action

SPN-446 – Drug Profile

Product Description

Mechanism Of Action

TNX-1600 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRN-110 – Drug Profile

Product Description

Mechanism Of Action

TRN-148 – Drug Profile

Product Description

Mechanism Of Action

TRN-176 – Drug Profile

Product Description

Mechanism Of Action

vafidemstat – Drug Profile

Product Description

Mechanism Of Action

History of Events

viloxazine hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0238429 – Drug Profile

Product Description

Mechanism Of Action

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones

Featured News & Press Releases

Feb 02, 2022: ABVC BioPharma announces principal investigator meeting for phase II part 2 ADHD clinical study

Dec 17, 2021: MindMed initiates phase 2a LSD trial for the treatment of adult ADHD

Nov 17, 2021: OWP Pharmaceuticals announces IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder

Nov 05, 2021: Tris Pharma announces FDA approval of DYANAVEL XR (amphetamine) once-daily extended-release oral tablets, CII, for ADHD

Oct 27, 2021: Central IRB approved for ABV-1505 phase II part II in Taiwan sites

Sep 13, 2021: ABVC BioPharma completes site selection for ABV-1505 ADHD phase II part 2 clinical study

Sep 02, 2021: Supernus announces Qelbree sNDA for adult indication accepted for review by FDA

Sep 01, 2021: ABVC BioPharma announces new PCT filings for MDD and ADHD treatments

Aug 05, 2021: Marvel Biosciences updates market on its lead caffeine inspired asset MB-204 for neurological diseases

Jul 22, 2021: Methylphenidate – use in pregnancy

May 24, 2021: Qelbree (viloxazine extended-release capsules), a new non-controlled substance, now available for the treatment of ADHD in pediatric patients 6-17 years of age

May 05, 2021: NLS Pharmaceutics announces patent issuance in Europe for its mazindol controlled-release formulation (mazindol CR)

Apr 22, 2021: OWP Pharmaceuticals announces patent application for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of Attention Deficit Hyperactivity Disorder

Apr 02, 2021: Supernus announces FDA approval of Qelbree (SPN-812) for the treatment of ADHD

Feb 22, 2021: Supernus receives FDA notice assigning early April 2021 PDUFA date for SPN-812 NDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 3Z ehf, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 4P-Pharma SAS, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by ABVC BioPharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by AgoneX Biopharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Altus Formulation Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arbor Pharmaceuticals LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Attentive Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Avekshan LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cennerv Pharma (S) Pte Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Commave Therapeutics SA, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Curemark LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DD Therapeutics LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DURECT Corp, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Eli Lilly and Co, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by EncepHeal Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Ensysce Biosciences Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Highland Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Hyloris Pharmaceuticals SA, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by INVENT Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Kashiv BioSciences LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by KemPharm Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Lennham Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by M et P Pharma AG, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Marvel Biotechnology Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by MD Healthcare Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Mind Medicine MindMed Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Mindset Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NeuroNascent Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NLS Pharmaceutics AG, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Nobias Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NutriBand Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Oryzon Genomics SA, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by OWP Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by P2D Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by PolyCore Therapeutics LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by RespireRx Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Reviva Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shenox Pharmaceuticals LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shionogi & Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Supernus Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Suven Life Sciences Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Taho Pharmaceuticals Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Tris Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Vallon Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Yuyu Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2022

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2022 (Contd..1)

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2022 (Contd..2)

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2022 (Contd..3)

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2022 (Contd..4)

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the targets of the ADHD pipeline drugs market?

    Some of the targets of the ADHD pipeline drugs market are Sodium Dependent Noradrenaline Transporter, Sodium Dependent Dopamine Transporter, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 1A, D2 Dopamine Receptor, D4 Dopamine Receptor, 5-Hydroxytryptamine Receptor, 5-Hydroxytryptamine Receptor 1B.

  • What are the mechanisms of action of the ADHD pipeline drugs market?

    Some of the mechanisms of action of the ADHD pipeline drugs market are Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D3 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Agonist, D4 Dopamine Receptor Agonist, and 5-Hydroxytryptamine Receptor 1B Agonist.

  • What are the routes of administration in the ADHD pipeline drugs market?

    The routes of administration in the ADHD pipeline drugs market are oral, transdermal, nasal, and subcutaneous.

  • What are the molecule types in the ADHD pipeline drugs market?

    The molecule types in the ADHD pipeline drugs market are small molecule, biologic, and enzyme.

  • Which are the key companies in the ADHD pipeline drugs market?

    Some of the key companies in the ADHD pipeline drugs market are 3Z ehf, NLS Pharmaceutics AG, Tris Pharma Inc, Supernus Pharmaceuticals Inc, Cingulate Therapeutics LLC, Ensysce Biosciences Inc, MD Healthcare Inc, 4P-Pharma SAS, ABVC BioPharma Inc, and AgoneX Biopharmaceuticals Inc.

Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.